Indian community organisations file first opposition against patent application
Development of d-d4FC (dexelvucitabine, Reverset) discontinued
2nd International Workshop on HIV & Women, 9-10 January 2012, Bethesda, USA 1 February 2012
Similar efficacy and a few gender related differences in side effects with rilpivirine vs efavirenz at 96-weeks 1 February 2012
Volume 13 Number 1/2 January/February 2012 1 February 2012
Supplement: HIV testing and risks of sexual transmission 1 February 2012
RSS Atom • ISSN 1472-4683 • Subscribe • About
Abbott announced on 4 April 2006 that it has filed for registration of meltrex lopinavir/r (non refrigerated) formulation in South Africa. The company also announced that this would be price-matched to the current formulation ($500 per patient, per year in Africa and the Least Developed Countries (LDCs).
Source: Abbott press release
http://www.abbott.com
Links to external websites are current at time of posting but not maintained.
HIV i-Base
Treatment phoneline: 0808 800 6013 • Mon-Wed 12-4pm • Office: 020 7407 8488 • Email: admin@i-base.org.uk • Website: www.i-base.info